Sanofi (SNY): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sanofi ( SNY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.4%. By the end of trading, Sanofi rose $0.74 (1.4%) to $52.54 on light volume. Throughout the day, 853,179 shares of Sanofi exchanged hands as compared to its average daily volume of 1,704,300 shares. The stock ranged in a price between $52.18-$52.56 after having opened the day at $52.40 as compared to the previous trading day's close of $51.80. Other companies within the Drugs industry that increased today were: Agios Pharmaceuticals ( AGIO), up 26.2%, Sangamo BioSciences ( SGMO), up 17.1%, Karyopharm Therapeutics ( KPTI), up 13.9% and La Jolla Pharmaceutical ( LJPC), up 12.7%.

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $138.5 billion and is part of the health care sector. Shares are down 3.1% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Zogenix ( ZGNX), down 14.5%, Cardiome Pharma Corporation ( CRME), down 11.7%, Kamada ( KMDA), down 11.3% and AVANIR Pharmaceuticals ( AVNR), down 11.0% , were all laggards within the drugs industry with Celgene Corporation ( CELG) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries